Enhancement of antibody selectivity via bicyclic complex formation

Journal of Physical Chemistry Letters

Volumn 3, Issue 5, 2012, Pages 598-602

  Stefanick, Jared F ^a   Kiziltepe, Tanyel ^a,b   Handlogten, Michael W ^a   Alves, Nathan J ^a   Bilgicer, Basar ^a,b  

^a University of Notre Dame   (United States)

^b UNIVERSITY OF NOTRE DAME   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALYTICAL ULTRACENTRIFUGATION; ANTIBODY BINDING; BICYCLIC COMPLEXES; BINDING AFFINITIES; COMPLEX FORMATIONS; HYDRODYNAMIC RADIUS; MOLAR RATIO; MONOMERIC FORMS; MULTIVALENT INTERACTIONS; POTENTIAL METHODS; THERAPEUTIC ANTIBODIES; THERMODYNAMICALLY STABLE;

ANTIGENS; BINDING ENERGY; CENTRIFUGATION;

ANTIBODIES;

EID: 84857765516     PISSN: None     EISSN: 19487185     Source Type: Journal    
DOI: 10.1021/jz201682z     Document Type: Article

References (25)

1. Brekke, O. H.; Sandlie, I. Therapeutic antibodies for human diseases at the dawn of the twenty-first century Nat. Rev. Drug Discov. 2003, 2, 52-62 (Pubitemid 37361624)
2. Drews, J. Drug discovery: A historical perspective Science 2000, 287, 1960-1964 (Pubitemid 30158662)
3. Safarik, I.; Safarikova, M. Use of magnetic techniques for the isolation of cells J. Chromatogr. B 1999, 722, 33-53 (Pubitemid 29142501)
4. Hoogenboom, H. R.; de Bruine, A. P.; Hufton, S. E.; Hoet, R. M.; Arends, J. W.; Roovers, R. C. Antibody phage display technology and its applications Immunotechnology 1998, 4, 1-20 (Pubitemid 28302180)
5. Casadevall, A.; Scharff, M. D. Return to the Past-the Case for Antibody-Based Therapies in Infectious-Diseases Clin. Infect. Dis. 1995, 21, 150-161
6. Lerner, R. A. Manufacturing immunity to disease in a test tube: The magic bullet realized Angew Chem., Int. Ed. 2006, 45, 8106-8125 (Pubitemid 44974142)
7. Holliger, P.; Hudson, P. Engineered antibody fragments and the rise of single domains Nat. Biotechnol. 2005, 23, 1126-1136 (Pubitemid 41486394)
8. Carlson, C. B.; Mowery, P.; Owen, R. M.; Dykhuizen, E. C.; Kiessling, L. L. Selective tumor cell targeting using low-affinity, multivalent interactions ACS Chem. Biol. 2007, 2, 119-127 (Pubitemid 47490233)
9. Stevenson, G. T. CD38 as a therapeutic target Mol. Med. 2006, 12, 345-346 (Pubitemid 46489831)
10. Ozcelik, C.; Erdmann, B.; Pilz, B.; Wettschureck, N.; Britsch, S.; Hubner, N.; Chien, K. R.; Birchmeier, C.; Garratt, A. N. Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy Proc. Natl. Acad. Sci. U. S. A. 2002, 99, 8880-8885 (Pubitemid 34693652)
11. Scott, C. T. The problem with potency Nat. Biotechnol. 2005, 23, 1037-1039 (Pubitemid 41486377)
12. Bria, E.; Cuppone, F.; Milella, M.; Verma, S.; Carlini, P.; Nistico, C.; Vaccaro, V.; Rossi, A.; Tonini, G.; Cognetti, F.; Terzoli, E. Trastuzumab cardiotoxicity: biological hypotheses and clinical open issues Expert Opin. Biol. Ther. 2008, 8, 1963-1971
13. Cersosimo, R. J. Monoclonal antibodies in the treatment of cancer, part 1 Am. J. Health- Syst. Pharm. 2003, 60, 1531-1548 (Pubitemid 44712921)
14. Schneider, J. W.; Chang, A. Y.; Rocco, T. P. Cardiotoxicity in signal transduction therapeutics: ErbB2 antibodies and the heart Semin. Oncol. 2001, 28, 18-26 (Pubitemid 33065106)
15. Chien, K. R. Focus on research: Herceptin and the heart-A molecular modifier of cardiac failure N. Engl. J. Med. 2006, 354, 789-790 (Pubitemid 43290916)
16. Perez, E. A. Cardiac toxicity of ErbB2-targeted therapies: What do we know? Clin. Breast Cancer 2008, 8, S114-S120
17. de Azambuja, E.; Bedard, P. L.; Suter, T.; Piccart-Gebhart, M. Cardiac toxicity with anti-HER-2 therapies-what have we learned so far? Target Oncol. 2009, 4, 77-88
18. Bilgicer, B.; Moustakas, D. T.; Whitesides, G. M. A synthetic trivalent hapten that aggregates anti-2,4-DNP IgG into bicyclic trimers J. Am. Chem. Soc. 2007, 129, 3722-3728 (Pubitemid 46502733)
19. Bilgicer, B.; Thomas, S. W.; Shaw, B. F.; Kaufman, G. K.; Krishnamurthy, V. M.; Estroff, L. A.; Yang, J.; Whitesides, G. M. A Non-Chromatographic Method for the Purification of a Bivalently Active Monoclonal IgG Antibody from Biological Fluids J. Am. Chem. Soc. 2009, 131, 9361-9367
20. Jiang, B. H.; Liu, W. B.; Qu, H.; Meng, L.; Song, S. M.; Tao, O. Y.; Shou, C. C. A novel peptide isolated from a phage display peptide library with trastuzumab can mimic antigen epitope of HER-2 J. Biol. Chem. 2005, 280, 4656-4662 (Pubitemid 40288635)
21. Riemer, A. B.; Klinger, M.; Wagner, S.; Bernhaus, A.; Mazzucchelli, L.; Pehamberger, H.; Scheiner, O.; Zielinski, C. C.; Jensen-Jarolim, E. Generation of peptide mimics of the epitope recognized by trastuzumab on the oncogenic protein Her-2/neu J. Immunol. 2004, 173, 394-401 (Pubitemid 38797365)
22. Garrett, J. T.; Rawale, S.; Allen, S. D.; Phillips, G.; Forni, G.; Morris, J. C.; Kaumaya, P. T. P. Novel engineered trastuzumab conformational epitopes demonstrate in vitro and in vivo antitumor properties against HER-2/neu J. Immunol. 2007, 178, 7120-7131 (Pubitemid 46847438)
23. Handlogten, M. W.; Kiziltepe, T.; Moustakas, D. T.; Bilgicer, B. Design of a Heterobivalent Ligand to Inhibit IgE Clustering on Mast Cells Chem. Biol. 2011, 18, 1179-1188
24. Reynolds, J. Interaction of Divalent Antibody with Cell-Surface Antigens Biochemistry 1979, 18, 264-269
25. Thompson, R.; Jackson, A. Cyclic Complexes and High Avidity Antibodies Trends Biochem. Sci. 1984, 9, 1-3 (Pubitemid 14191459)